MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Myriad Genetics Inc (MYGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and neutral trading sentiment. While the technical indicators are neutral, the absence of strong buy signals and poor financial trends suggest holding off on investment for now.
The MACD histogram is positive at 0.0389 but contracting, RSI is neutral at 43.272, and moving averages are converging. The stock is trading near its pivot level of 4.861, with resistance at 5.262 and support at 4.46. Overall, no clear bullish or bearish trend is evident.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Weak financial performance in Q4 2025 with significant declines in revenue (-0.38% YoY), net income (-81.41% YoY), and EPS (-82.98% YoY). Analysts have lowered price targets, and the stock lacks clear growth or profitability visibility.
In Q4 2025, revenue dropped to $209.8M (-0.38% YoY), net income fell to -$7.9M (-81.41% YoY), EPS declined to -0.08 (-82.98% YoY), and gross margin decreased to 69.97% (-2.34% YoY). Overall, the company is underperforming financially.
Analysts have lowered price targets (UBS to $6 from $8, Wells Fargo to $6 from $6.50) and maintain neutral ratings. Analysts are cautious, awaiting progress on turnaround strategy and pipeline execution.
